<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556838</url>
  </required_header>
  <id_info>
    <org_study_id>VVN001-CS-201</org_study_id>
    <nct_id>NCT04556838</nct_id>
  </id_info>
  <brief_title>Study of VVN001 Ophthalmic Solution in Dry Eye Disease</brief_title>
  <official_title>A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VivaVision Biotech, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VivaVision Biotech, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled,&#xD;
      parallel-group study designed to evaluate the safety and tolerability and to explore the&#xD;
      efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-masked parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inferior Corneal Fluorescein Staining</measure>
    <time_frame>Day 84</time_frame>
    <description>Mean change from baseline in Inferior corneal fluorescein staining</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Corneal Fluorescein Staining</measure>
    <time_frame>Each visit through Day 84</time_frame>
    <description>Mean change from baseline in total corneal fluorescein staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Corneal Fluorescein Staining</measure>
    <time_frame>Each visit through Day 84</time_frame>
    <description>Mean change from baseline in each regional corneal fluorescein staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye Dryness</measure>
    <time_frame>Each visit through Day 84</time_frame>
    <description>Eye Dryness VAS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">169</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>VVN001, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VVN001, 1% ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VVN001, 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VVN001, 5% ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VVN001 Ophthalmic Solution Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VVN001 Ophthalmic Solution 1%</intervention_name>
    <description>VVN001 Ophthalmic Solution 1%</description>
    <arm_group_label>VVN001, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VVN001 Ophthalmic Solution 5%</intervention_name>
    <description>VVN001 Ophthalmic Solution 5%</description>
    <arm_group_label>VVN001, 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>VVN001 Ophthalmic Solution Vehicle</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent prior to any study-related procedures .&#xD;
&#xD;
          -  Are 18 years of age or older.&#xD;
&#xD;
          -  Are willing and able to follow instructions and willing to be present for the required&#xD;
             study visits for the duration of the study.&#xD;
&#xD;
          -  Have a best corrected visual acuity (BCVA), using corrective lenses if necessary, in&#xD;
             the qualifying eye(s) of +0.7 or better as assessed by Early Treatment of Diabetic&#xD;
             Retinopathy Study (ETDRS) at the screening visit and randomization visit.&#xD;
&#xD;
          -  Have a history of dry eye disease in both eyes&#xD;
&#xD;
          -  Are currently using artificial tears and have been using within 30 days of the&#xD;
             screening visit.&#xD;
&#xD;
          -  Have an Eye dryness score ≥40 at Visit 1 and ≥35 at Visit 2, one score for both eyes&#xD;
             (0-100 point VAS)&#xD;
&#xD;
          -  Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the&#xD;
             following criteria in the study eye and the same eye at Visit 1 and Visit 2:&#xD;
&#xD;
          -  Inferior CFS (iCFS) score of ≥2 (NEI; 0-4 scale; using 0.5 unit increments)&#xD;
&#xD;
          -  Have a Schirmer score (without anesthesia) of ≥1 and ≤7 mm/5 min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known hypersensitivity or contraindication to the IP or components of IP.&#xD;
&#xD;
          -  Have a Schirmer score (without anesthesia) of &lt;1 or &gt;7 mm/5 min in the study eye.&#xD;
&#xD;
          -  Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening&#xD;
             visit or are being treated with eye drops for glaucoma in the study eye. Or the&#xD;
             subject has had laser or surgery for glaucoma in the study eye within 90 days of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lexitas</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

